Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.
Year: 2010
Type: article
Source: PubMed
Authors: Janina Geiler, Michael F McDermott
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: gevokizumab, IL-1β, anti-IL-1β monoclonal antibody, type 1 diabetes, type 2 diabetes, rheumatoid arthritis, cardiovascular disease, uveitis, Behçet's disease, familial cold autoinflammatory syndrome, Muckle-Wells syndrome, autoinflammatory disease, vasculitis, humanized monoclonal antibody, innate immunity, anti-inflammatory therapy
Open Access status: closed
OpenAlex ID: W48003056
